Leeb Burkhard F, Rintelen Bernhard, Sautner Judith, Fassl Christian, Bird Howard A
Lower Austrian Center for Rheumatology, State Hospital Stockerau, Stockerau, Austria.
Arthritis Rheum. 2007 Jun 15;57(5):810-5. doi: 10.1002/art.22771.
To confirm the reliability and applicability of the Polymyalgia Rheumatica Disease Activity Score (PMR-AS), and to establish a threshold for remission.
First, 78 patients with PMR (50 women/28 men, mean age 65.97 years) were enrolled in a cross-sectional evaluation. The PMR-AS, patient's satisfaction with disease status (PATSAT; range 1-5), erythrocyte sedimentation rate (ESR; first hour), and a visual analog scale of patients' general health assessment (VAS patient global; range 0-100) were recorded. Subsequently, another 39 PMR patients (24 women/15 men, mean age 68.12 years) were followed longitudinally. Relationships between the PMR-AS, PATSAT, ESR, and VAS patient global were analyzed by the Kruskal-Wallis test, Spearman's rank correlation, and kappa statistics. PMR-AS values in patients with a PATSAT score of 1 and a VAS patient global <10 formed the basis to establish a remission threshold.
PMR-AS values were significantly related to PATSAT (P < 0.001), VAS patient global (P < 0.001), and ESR (P < 0.01). PATSAT and VAS patient global were reasonably different (kappa = 0.226). The median PMR-AS score in patients with PATSAT score 1 and VAS patient global <10 was 0.7 (range 0-3.3), and the respective 75th percentile was 1.3. To enhance applicability, a range from 0 to 1.5 was proposed to define remission in PMR. The median ESR in these patients was 10 mm/hour (range 3-28), indicating external validity.
We demonstrated the reliability, validity, and applicability of the PMR-AS in daily routine. Moreover, we proposed a remission threshold (0-1.5) founded on patient-dependent parameters.
确认风湿性多肌痛疾病活动评分(PMR-AS)的可靠性和适用性,并确定缓解阈值。
首先,纳入78例风湿性多肌痛患者(50例女性/28例男性,平均年龄65.97岁)进行横断面评估。记录PMR-AS、患者对疾病状态的满意度(PATSAT;范围1-5)、红细胞沉降率(ESR;第1小时)以及患者总体健康评估的视觉模拟量表(VAS患者总体;范围0-100)。随后,对另外39例风湿性多肌痛患者(24例女性/15例男性,平均年龄68.12岁)进行纵向随访。通过Kruskal-Wallis检验、Spearman秩相关和kappa统计分析PMR-AS、PATSAT、ESR和VAS患者总体之间的关系。PATSAT评分为1且VAS患者总体<10的患者的PMR-AS值构成了确定缓解阈值的基础。
PMR-AS值与PATSAT(P<0.001)、VAS患者总体(P<0.001)和ESR(P<0.01)显著相关。PATSAT和VAS患者总体存在合理差异(kappa=0.226)。PATSAT评分为1且VAS患者总体<10的患者的PMR-AS评分中位数为0.7(范围0-3.3),相应的第75百分位数为1.3。为提高适用性,建议采用0至1.5的范围来定义风湿性多肌痛的缓解。这些患者的ESR中位数为10毫米/小时(范围3-28),表明具有外部效度。
我们证明了PMR-AS在日常临床中的可靠性、有效性和适用性。此外,我们基于患者相关参数提出了一个缓解阈值(0-1.5)。